NRXP NRx Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 11:25
Why NRXP matters now
NRx Pharmaceuticals, Inc. (NRXP) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.03 with +2.68% on the session and $69.6M in market capitalization; recent performance reads 1-month +31.02% and YTD +46.49%.
The latest financial table shown here is Q1 2026, with revenue of $1.1M, net income of $-1.4M, and EPS of $-0.04. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -21.8%.
The latest indexable market news headline is "NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.00; recent insider activity includes Casper Joseph Michael filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-9.29
P/S
29.93
EV/EBITDA
-2.69
DCF Value
$0.72
FCF Yield
-21.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.1%
Operating Margin
-749.7%
Net Margin
-1070.3%
ROE
107.7%
ROA
-206.2%
ROIC
133.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.1M | $-1.4M | $-0.04 |
| Q4 2025 | $983.0K | $360.0K | $0.01 |
| FY 2025 | $1.2M | $-28.6M | $-1.34 |
| Q3 2025 | $242.0K | $-5.9M | $-0.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.00
Target (Median)
$2.00
Target Range
$2.00 - $2.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.19
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.